Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Drug Discov Today. 2019 Sep 18;25(1):89–106. doi: 10.1016/j.drudis.2019.09.009

FIGURE 3.

FIGURE 3

Schematic representation of improved oxcarbazepine (OXC) penetration across the blood–brain barrier (BBB). The nonsilenced or noninhibited epileptic brain endothelial cells (EPI-EC) demonstrated increased drug metabolic potency at the BBB. Conversely, silencing the GR in EPI-ECs resulted in a reduction of OXC metabolism compared with nonsilenced conditions in EPI-ECs. In this manner, the penetration of OXC across the BBB EPI-ECs was improved upon GR silencing or inhibition [59].